BioSpace News Archive

SNIPR Biome, a pioneer in the development CRISPR-Cas armed phages to prevent and treat bacterial infections, announced that it has received funding from the Bill & Melinda Gates Foundation to develop a microbiome-directed intervention designed to improve environmental enteric dysfunction by reducing gut entero-pathogen burden in pregnant women from low- and middle-income countries.

Merck announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the approval of WINREVAIR.

23andMe Holding Co. and Nightingale Health Plc announced a strategic collaboration to pilot Nightingale Health’s clinically-validated and cost-effective blood metabolomics panel with a cohort of 23andMe members.

Apellis Pharmaceuticals, Inc. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a negative opinion on the marketing authorization application of intravitreal pegcetacoplan for the treatment of geographic atrophy.

Mytonomy Inc., a leader in cloud solutions for health education and engagement, announced that the company is a proud participant of the American Academy of Orthopaedic Surgeons’ Patient-Reported Outcome Measures Vendor Program.

Allurion Technologies, Inc. today announced the pricing of an underwritten public offering of 14,406,508 shares of its common stock, par value $0.0001 per share (the “Shares”), and warrants to purchase 14,406,508 Shares.

A dispute between Daiichi Sankyo Co., Ltd. (TSE: 4568) and Seagen Inc. is now concluded and Seagen has paid Daiichi Sankyo approximately U.S. $47 million in connection with attorneys’ fees and costs plus interest awarded by the arbitrator of the party’s dispute.

NLS Pharmaceutics Ltd. announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 3,277,750 of its common shares at a purchase price of $0.24 per share in a registered direct offering.

Oryzon Genomics, S.A. announced the voting results from its Annual General Meeting of Shareholders held in Madrid.

Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced two poster presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN), taking place June 29-July 2, 2024 in Helsinki.